HC Wainwright Cuts Immunic (NASDAQ:IMUX) Price Target to $8.00
HC Wainwright lowered Immunic's (NASDAQ:IMUX) target price from $10.00 to $8.00, maintaining a "buy" rating. Other analysts also adjusted their ratings, with some setting lower targets and others issuing "buy" ratings. Immunic's stock performance and institutional investor activities were highlighted. The company focuses on developing treatments for chronic inflammatory and autoimmune diseases. Recent earnings showed a slight beat on EPS estimates. The stock has a consensus rating of "Moderate Buy" with a target price of $7.40.
Immunic (NASDAQ:IMUX - Get Free Report) had its target price dropped by research analysts at HC Wainwright from $10.00 to $8.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm presently has a "buy" rating on the stock.
Several other equities analysts have also recently weighed in on IMUX. D. Boral Capital decreased their price objective on Immunic from $10.00 to $8.00 and set a "buy" rating for the company in a report on Thursday. Weiss Ratings restated a "sell (d-)" rating on shares of Immunic in a report on Wednesday, October 8th. Roth Capital started coverage on Immunic in a report on Friday, November 7th. They set a "buy" rating and a $3.00 target price on the stock. LADENBURG THALM/SH SH raised Immunic to a "strong-buy" rating in a research note on Thursday, October 16th. Finally, Chardan Capital started coverage on Immunic in a research note on Monday, September 29th. They issued a "buy" rating and a $13.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Immunic presently has a consensus rating of "Moderate Buy" and a consensus price target of $7.40.
View Our Latest Stock Analysis on Immunic
Immunic Price Performance
Shares of IMUX stock traded up $0.03 during trading hours on Friday, reaching $0.74. The company had a trading volume of 364,413 shares, compared to its average volume of 1,285,254. The firm has a market cap of $73.20 million, a price-to-earnings ratio of -0.79 and a beta of 1.53. Immunic has a 1-year low of $0.56 and a 1-year high of $1.42. The company has a 50 day moving average of $0.83 and a 200 day moving average of $0.87.
Immunic (NASDAQ:IMUX - Get Free Report) last announced its earnings results on Thursday, November 13th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.05. As a group, sell-side analysts forecast that Immunic will post -0.94 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of the stock. Aberdeen Group plc bought a new position in Immunic during the 1st quarter valued at $1,155,000. 683 Capital Management LLC boosted its holdings in Immunic by 28.6% during the first quarter. 683 Capital Management LLC now owns 900,000 shares of the company's stock worth $981,000 after purchasing an additional 200,000 shares during the last quarter. Jane Street Group LLC grew its position in Immunic by 279.3% in the 1st quarter. Jane Street Group LLC now owns 207,401 shares of the company's stock worth $226,000 after purchasing an additional 152,726 shares in the last quarter. Focus Partners Wealth increased its stake in Immunic by 19.1% in the 1st quarter. Focus Partners Wealth now owns 2,583,457 shares of the company's stock valued at $2,816,000 after buying an additional 415,104 shares during the last quarter. Finally, HB Wealth Management LLC bought a new position in shares of Immunic in the third quarter valued at approximately $81,000. Institutional investors own 51.82% of the company's stock.
Immunic Company Profile
(Get Free Report)Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
See Also
- Five stocks we like better than Immunic
- EV Stocks and How to Profit from Them
- LightPath Stock Eyes 50% Upside on Defense Demand Surge
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- CRWD Stock Hits Key Inflection Point Ahead of Earnings
- Why Are Stock Sectors Important to Successful Investing?
- Rigetti’s Q3 Miss Reveals Quantum Funding and Timing Pressures
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Immunic Right Now?
Before you consider Immunic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunic wasn't on the list.
While Immunic currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
